Compare OLP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | MLYS |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 3.1B |
| IPO Year | N/A | 2023 |
| Metric | OLP | MLYS |
|---|---|---|
| Price | $20.35 | $35.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $47.33 |
| AVG Volume (30 Days) | 107.8K | ★ 1.5M |
| Earning Date | 11-06-2025 | 02-11-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $97,423,000.00 | N/A |
| Revenue This Year | $7.95 | N/A |
| Revenue Next Year | $6.06 | N/A |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | ★ 9.29 | N/A |
| 52 Week Low | $19.62 | $8.24 |
| 52 Week High | $28.36 | $47.65 |
| Indicator | OLP | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 36.08 |
| Support Level | $19.86 | $36.50 |
| Resistance Level | $21.66 | $37.75 |
| Average True Range (ATR) | 0.35 | 1.65 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 28.31 | 10.70 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.